Clinical Trials Browser

Phase 1/2 × OTHER × Magnetic Resonance Spectroscopy × Clear all

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Prostatic Neoplasms

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT07150806 2026-04-17

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Phase 1/2 Suspended

Meningioma

NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Phase 1/2 Not yet recruiting

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07225985 2026-04-03

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT07181941 2026-03-27

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06232044 2026-03-25

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT05888532 2026-03-17

64Cu-GRIP B in Patients With Advanced Malignancies

Phase 1/2 Recruiting

Kidney Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Lipodystrophy, Congenital Generalized

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06504381 2026-03-11

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Phase 1/2 Recruiting

Glioma

NCT06502691 2026-03-02

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT06536049 2026-02-19

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07420959 2026-02-19

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Phase 1/2 Not yet recruiting

Waldenstrom Macroglobulinemia

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06307548 2026-02-10

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Phase 1/2 Suspended

Gastrointestinal

Colorectal Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT07098364 2026-01-14

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06320405 2025-12-29

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02068794 2025-11-18

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 1/2 Active not recruiting

34 enrolled 12 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05558904 2025-11-10

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Phase 1/2 Recruiting

Adenocarcinoma of Lung

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06572605 2025-09-19

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

Phase 1/2 Recruiting

Multiple Myeloma

NCT06866262 2025-09-09

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Phase 1/2 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06026657 2025-07-08

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Phase 1/2 Recruiting

Anatomic Stage IV Breast Cancer AJCC v8

NCT07042919 2025-06-29

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

Triple Negative Breast Neoplasms

NCT02730546 2025-06-22

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Phase 1/2 Completed

31 enrolled 20 charts

Gastrointestinal

Stomach Neoplasms

NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase 1/2 Completed

38 enrolled 17 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05599048 2025-03-24

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06249191 2025-03-24

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Phase 1/2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06110572 2024-06-20

TESSERACT

Phase 1/2 Recruiting

Lung Neoplasms

NCT03949517 2024-01-30

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Phase 1/2 Completed

14 enrolled 7 charts

Prostatic Neoplasms

NCT03831711 2023-12-13

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Phase 1/2 Completed

5 enrolled 6 charts

Breast Neoplasms

NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Phase 1/2 Withdrawn

Uveal Melanoma

NCT02177773 2019-11-12

DOTA-TOC

Phase 1/2 Terminated

300 enrolled 5 charts

CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

NCT02488070 2018-03-20

68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

Phase 1/2 Completed

10 enrolled 8 charts

Prostatic Neoplasms

NCT00471835 2017-01-19

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms